DK3850946T5 - Ikke-humane dyr med en humaniseret klynge af differentiering af 47-gen - Google Patents

Ikke-humane dyr med en humaniseret klynge af differentiering af 47-gen Download PDF

Info

Publication number
DK3850946T5
DK3850946T5 DK20215046.2T DK20215046T DK3850946T5 DK 3850946 T5 DK3850946 T5 DK 3850946T5 DK 20215046 T DK20215046 T DK 20215046T DK 3850946 T5 DK3850946 T5 DK 3850946T5
Authority
DK
Denmark
Prior art keywords
humanized
differentiation
human animals
gene cluster
cluster
Prior art date
Application number
DK20215046.2T
Other languages
Danish (da)
English (en)
Other versions
DK3850946T3 (da
Inventor
Cagan Gurer
Ella Ioffe
Alexander Mujica
Gavin Thurston
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54979926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3850946(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK3850946T3 publication Critical patent/DK3850946T3/da
Publication of DK3850946T5 publication Critical patent/DK3850946T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
DK20215046.2T 2014-12-05 2015-11-25 Ikke-humane dyr med en humaniseret klynge af differentiering af 47-gen DK3850946T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462087992P 2014-12-05 2014-12-05
EP18207075.5A EP3466255B1 (en) 2014-12-05 2015-11-25 Non-human animals having a humanized cluster of differentiation 47 gene

Publications (2)

Publication Number Publication Date
DK3850946T3 DK3850946T3 (da) 2024-01-08
DK3850946T5 true DK3850946T5 (da) 2024-08-19

Family

ID=54979926

Family Applications (3)

Application Number Title Priority Date Filing Date
DK20215046.2T DK3850946T5 (da) 2014-12-05 2015-11-25 Ikke-humane dyr med en humaniseret klynge af differentiering af 47-gen
DK18207075.5T DK3466255T3 (da) 2014-12-05 2015-11-25 Ikke-humane dyr med en humaniseret klynge af differentiering af 47-gen
DK15813960.0T DK3086637T3 (en) 2014-12-05 2015-11-25 NON-HUMAN ANIMALS WITH A HUMANIZED CLUSTER OF DIFFERENTIATION 47 GEN

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK18207075.5T DK3466255T3 (da) 2014-12-05 2015-11-25 Ikke-humane dyr med en humaniseret klynge af differentiering af 47-gen
DK15813960.0T DK3086637T3 (en) 2014-12-05 2015-11-25 NON-HUMAN ANIMALS WITH A HUMANIZED CLUSTER OF DIFFERENTIATION 47 GEN

Country Status (29)

Country Link
US (5) US20160345549A1 (https=)
EP (4) EP4296278A3 (https=)
JP (2) JP6730277B2 (https=)
KR (3) KR102508175B1 (https=)
CN (2) CN107205368B (https=)
AR (1) AR102888A1 (https=)
AU (2) AU2015355328B2 (https=)
BR (1) BR112017010490A2 (https=)
CA (1) CA2967834C (https=)
CY (2) CY1121547T1 (https=)
DK (3) DK3850946T5 (https=)
ES (3) ES2969389T3 (https=)
FI (1) FI3850946T3 (https=)
HR (3) HRP20231707T1 (https=)
HU (3) HUE064960T2 (https=)
IL (2) IL286403B2 (https=)
LT (3) LT3466255T (https=)
MX (1) MX2017007293A (https=)
NZ (2) NZ731471A (https=)
PL (3) PL3086637T3 (https=)
PT (3) PT3466255T (https=)
RS (3) RS58536B1 (https=)
RU (1) RU2728412C2 (https=)
SG (2) SG11201703463WA (https=)
SI (3) SI3850946T1 (https=)
SM (3) SMT202100281T1 (https=)
TR (1) TR201903891T4 (https=)
TW (1) TWI681053B (https=)
WO (1) WO2016089692A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE064960T2 (hu) 2014-12-05 2024-04-28 Regeneron Pharma Differenciációs 47 gén humanizált klasztert tartalmazó nem-humán állatok
CN113412818B (zh) 2014-12-09 2022-11-04 瑞泽恩制药公司 具有人源化分化簇274基因的非人动物
WO2016154299A1 (en) * 2015-03-24 2016-09-29 The Trustees Of Columbia University In The City Of New York Genetic modification of pigs for xenotransplantation
AU2016270587B2 (en) 2015-05-29 2020-12-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a disruption in a C9ORF72 locus
WO2017087780A1 (en) 2015-11-20 2017-05-26 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3
SG11201806176PA (en) 2016-02-04 2018-08-30 Regeneron Pharma Non-human animals having an engineered angptl8 gene
DK3422845T3 (da) 2016-02-29 2021-08-30 Regeneron Pharma Gnavere med et humaniseret tmprss-gen
SG11201901107RA (en) * 2016-08-11 2019-03-28 Jackson Lab Methods and compositions relating to improved human red blood cell survival in genetically modified immunodeficient non-human animals
CN107815468B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
US11279948B2 (en) 2016-08-31 2022-03-22 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric OX40
WO2018041121A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric ctla-4
CN107815465B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
CN109862785B (zh) * 2016-09-30 2022-09-06 瑞泽恩制药公司 C9orf72基因座中具有六核苷酸重复扩增的非人类动物
CN108467873B (zh) 2017-03-17 2020-03-13 百奥赛图江苏基因生物技术有限公司 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用
CN108588126B (zh) * 2017-03-31 2020-04-10 北京百奥赛图基因生物技术有限公司 Cd47基因人源化改造动物模型的制备方法及应用
WO2018177441A1 (en) * 2017-03-31 2018-10-04 Beijing Biocytogen Co., Ltd GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα
IL270835B2 (en) * 2017-06-12 2025-01-01 Sinai Health Sys Allograft tolerance without the need for systemic immunosuppression
JP7262440B2 (ja) 2017-08-02 2023-04-21 フェインズ セラピューティクス，インコーポレーテッド 抗ｃｄ４７抗体及びその使用
JP7361031B2 (ja) * 2017-11-30 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物
IL314733A (en) * 2018-03-26 2024-10-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
HRP20240999T1 (hr) 2018-07-16 2024-10-25 Regeneron Pharmaceuticals, Inc. Glodavački modeli bolesti ditra i njihova upotreba
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR102925054B1 (ko) 2018-12-20 2026-02-10 리제너론 파마슈티칼스 인코포레이티드 뉴클레아제-매개 반복부 팽창
CN114107385A (zh) * 2019-01-17 2022-03-01 百奥赛图(北京)医药科技股份有限公司 人源化转基因动物
WO2021027737A1 (en) * 2019-08-09 2021-02-18 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric il2ra
CN112553252B (zh) * 2019-09-06 2022-04-29 百奥赛图(北京)医药科技股份有限公司 Tnfr2基因人源化的非人动物的构建方法和应用
US20230058049A1 (en) * 2019-12-31 2023-02-23 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED IMMUNODEFICIENT NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPa/CD47
CN112080522A (zh) * 2020-09-15 2020-12-15 广东药康生物科技有限公司 一种cd47人源化小鼠模型的构建方法
CN112725379B (zh) * 2021-01-27 2024-08-13 上海南方模式生物科技股份有限公司 人源化cd40基因改造动物模型的构建方法及应用
WO2023046061A1 (en) * 2021-09-24 2023-03-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric trop2
IL318159A (en) 2022-07-19 2025-03-01 Regeneron Pharma Genetically modified animal model and its use to model the human immune system
US20250255282A1 (en) 2024-02-08 2025-08-14 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2545166A1 (en) * 2003-11-11 2005-05-19 Chugai Seiyaku Kabushiki Kaisha Humanized anti-cd47 antibody
ES2463476T3 (es) 2004-10-19 2014-05-28 Regeneron Pharmaceuticals, Inc. Método para generar un ratón homocigótico para una modificación genética
WO2007033221A2 (en) * 2005-09-13 2007-03-22 The General Hospital Corporation Methods and compositions for inhibition of immune responses
PE20081216A1 (es) * 2006-09-01 2008-09-04 Therapeutic Human Polyclonals Inc Expresion mejorada de la inmunoglobulina humana o humanizada en animales transgenicos no humanos
WO2009039244A2 (en) * 2007-09-18 2009-03-26 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
CN101668387A (zh) 2008-09-02 2010-03-10 鸿富锦精密工业（深圳）有限公司 印刷电路板
CN102281758B (zh) * 2009-01-16 2014-12-10 公益财团法人实验动物中央研究所 移植了人肝细胞的小鼠
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
US8518392B2 (en) 2009-08-14 2013-08-27 Regeneron Pharmaceuticals, Inc. Promoter-regulated differentiation-dependent self-deleting cassette
CA2771336C (en) * 2009-09-15 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
EP4502152A3 (en) 2009-10-06 2025-04-30 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
SG10202008003VA (en) 2011-02-15 2020-10-29 Regeneron Pharma Humanized m-csf mice
WO2013056352A1 (en) * 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
SMT202200205T1 (it) 2011-10-28 2022-07-21 Regeneron Pharma Topi geneticamente modificati che esprimono molecole chimeriche del complesso maggiore di istocompatibilità (mhc) ii
SMT201900478T1 (it) 2011-10-28 2019-09-09 Regeneron Pharma Topi con complesso maggiore di istocompatibilita' geneticamente modificati
CN108866101A (zh) * 2011-10-28 2018-11-23 瑞泽恩制药公司 人源化il-6和il-6受体
EP2644027A1 (en) * 2012-03-26 2013-10-02 Institut Pasteur Transgenic immunodefficient mouse expressing human SIRPalpha.
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
FI2892330T3 (fi) 2012-09-07 2023-03-25 Univ Yale Geneettisesti muokattuja hiiriä ja menetelmiä niiden käyttämiseksi
MX377561B (es) 2012-11-05 2025-03-10 Regeneron Pharma Animales no humanos genéticamente modificados y métodos de uso de los mismos.
BR112015013431A2 (pt) * 2012-12-12 2017-11-14 Vasculox Inc anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos
CN111484999B (zh) 2013-02-20 2024-10-25 瑞泽恩制药公司 人源化的t细胞共受体的小鼠
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
EP3699190B9 (en) 2013-02-22 2023-10-04 Regeneron Pharmaceuticals, Inc. Murine cell expressing humanized major histocompatibility complex
TR201901782T4 (tr) 2013-09-23 2019-03-21 Regeneron Pharma İnsanlaştirilmiş bi̇r si̇nyal düzenleyi̇ci̇ protei̇n geni̇ne sahi̇p olan i̇nsan dişi hayvanlar.
ES2613379T3 (es) 2013-10-15 2017-05-24 Regeneron Pharmaceuticals, Inc. Animales con IL-15 humanizada
CA2929846C (en) 2013-11-19 2020-09-15 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
RU2671101C1 (ru) 2013-11-19 2018-10-29 Регенерон Фармасьютикалс, Инк. Отличные от человека животные, содержащие гуманизированный ген индуцирующего пролиферацию лиганда
CN111690052B (zh) 2014-04-08 2024-06-04 瑞泽恩制药公司 具有人源化FC-γ受体的非人动物
NO2785538T3 (https=) 2014-05-07 2018-08-04
MX2016014995A (es) 2014-05-19 2017-03-31 Regeneron Pharma Animales no humanos geneticamente modificados que expresan eritropoyetina de humano.
IL287519B2 (en) 2014-06-19 2024-01-01 Regeneron Pharma Non-human animals having a humanized programmed cell death 1 gene
RU2726446C2 (ru) 2014-11-24 2020-07-14 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3
HUE064960T2 (hu) 2014-12-05 2024-04-28 Regeneron Pharma Differenciációs 47 gén humanizált klasztert tartalmazó nem-humán állatok

Also Published As

Publication number Publication date
SG10202103050YA (en) 2021-05-28
US20160157470A1 (en) 2016-06-09
LT3086637T (lt) 2019-04-10
AU2022203787B2 (en) 2025-01-30
RS58536B1 (sr) 2019-04-30
JP7089554B2 (ja) 2022-06-22
CY1121547T1 (el) 2020-05-29
IL252019A0 (en) 2017-06-29
NZ731471A (en) 2021-12-24
KR20170098800A (ko) 2017-08-30
TWI681053B (zh) 2020-01-01
IL286403B2 (en) 2023-10-01
RS61774B1 (sr) 2021-05-31
SI3466255T1 (sl) 2021-07-30
HRP20210662T1 (hr) 2021-05-28
LT3850946T (lt) 2024-01-10
US20240138384A1 (en) 2024-05-02
EP4296278A2 (en) 2023-12-27
EP3086637A1 (en) 2016-11-02
FI3850946T3 (fi) 2023-12-28
ES2870462T3 (es) 2021-10-27
PL3850946T3 (pl) 2024-03-11
JP2018500012A (ja) 2018-01-11
WO2016089692A1 (en) 2016-06-09
KR20210127773A (ko) 2021-10-22
HRP20231707T1 (hr) 2024-03-15
CA2967834C (en) 2024-01-16
KR20230038599A (ko) 2023-03-20
TW201629210A (zh) 2016-08-16
HK1225912A1 (en) 2017-09-22
EP4296278A3 (en) 2024-03-27
PT3086637T (pt) 2019-03-26
PT3850946T (pt) 2024-01-02
RU2017123357A3 (https=) 2019-06-03
US11910788B2 (en) 2024-02-27
CN112342197A (zh) 2021-02-09
PL3086637T3 (pl) 2019-09-30
RS64989B1 (sr) 2024-01-31
PT3466255T (pt) 2021-05-10
HUE043132T2 (hu) 2019-07-29
HUE054661T2 (hu) 2021-09-28
BR112017010490A2 (pt) 2018-04-03
SMT202100281T1 (it) 2021-07-12
CA2967834A1 (en) 2016-06-09
DK3850946T3 (da) 2024-01-08
EP3850946B1 (en) 2023-09-27
EP3850946A1 (en) 2021-07-21
CN107205368A (zh) 2017-09-26
AU2022203787A1 (en) 2022-06-23
TR201903891T4 (tr) 2019-04-22
NZ769992A (en) 2024-11-29
US20210161112A1 (en) 2021-06-03
KR102508175B1 (ko) 2023-03-09
IL286403A (en) 2021-10-31
HUE064960T2 (hu) 2024-04-28
DK3466255T3 (da) 2021-05-03
DK3086637T3 (en) 2019-04-08
CN112342197B (zh) 2025-02-18
EP3466255B1 (en) 2021-02-17
RU2017123357A (ru) 2019-01-09
AR102888A1 (es) 2017-03-29
JP2020168016A (ja) 2020-10-15
EP3466255A1 (en) 2019-04-10
US10015953B2 (en) 2018-07-10
KR102313073B1 (ko) 2021-10-18
HRP20190634T1 (hr) 2019-08-09
IL286403B1 (en) 2023-06-01
US12389889B2 (en) 2025-08-19
IL252019B (en) 2021-10-31
ES2969389T3 (es) 2024-05-17
MX2017007293A (es) 2018-03-12
RU2728412C2 (ru) 2020-07-29
US10939673B2 (en) 2021-03-09
EP3086637B1 (en) 2019-01-02
AU2015355328B2 (en) 2022-03-10
SI3086637T1 (sl) 2019-04-30
LT3466255T (lt) 2021-05-25
US20160345549A1 (en) 2016-12-01
KR102617691B1 (ko) 2023-12-27
ES2716735T3 (es) 2019-06-14
AU2015355328A1 (en) 2017-05-18
SI3850946T1 (sl) 2024-02-29
SMT202300482T1 (it) 2024-01-10
CN107205368B (zh) 2020-11-17
SMT201900178T1 (it) 2019-05-10
CY1124089T1 (el) 2022-05-27
SG11201703463WA (en) 2017-05-30
PL3466255T3 (pl) 2021-08-09
US20180249689A1 (en) 2018-09-06
JP6730277B2 (ja) 2020-07-29

Similar Documents

Publication Publication Date Title
DK3850946T3 (da) Ikke-humane dyr med en humaniseret klynge af differentiering af 47-gen
DK3808775T3 (da) Ikke-humaniserede dyr med en klynge af differenteringsgenet 274
IL249465A0 (en) Object avoidance for automated aerial vehicles
SMT201700024B (it) Animali con il-15 umanizzata
DK2971920T3 (da) Rørforbindelse med automatisk forbindelse
DK3560954T3 (da) Modificeret j-kæde
HUE051811T2 (hu) Õrzési periódus konfiguráció LTE HD-FDD céljára
KR20180085002A (ko) 인간화된 항-cll-1 항체
BR112016015364A2 (pt) Injetor automático
DK3129400T3 (da) Ikke-humane dyr med humaniserede Fc-gamma-receptorer
EP3374873A4 (en) PREDICTIVE MAINTENANCE
FI20145100L (fi) Magneetti
DK4268843T3 (da) Forbedrede IL-6-antistoffer
EP3519295A4 (en) OBLIQUE ROTARY WING AIRCRAFT
BR112017008678A2 (pt) fabricação de aditivo
DK3294287T3 (da) Oxabicycloheptan-prodrugs
MA43962A (fr) Animaux non humains possédant un gène angptl8 modifié
FI20145103L (fi) Magneetti
DK3188963T3 (da) Forbedring af en skrue
FR3021432B1 (fr) Processeur a instructions conditionnelles
FR3046256B1 (fr) Zoom plenoptique a portee optimisee
EP3206627C0 (en) IMPROVED LENS DESIGN
EP3153913C0 (en) PROGRESSIVE POWER LENS
FR3018564B1 (fr) Insert filete
DK3192852T3 (da) Brændstofadditiv